Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for ...

A class action lawsuit was filed against Cassava Sciences Inc. (SAVA) by Levi & Korsinsky on December 12, 2024. The ...

Take two at bedtime.

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer's disease candidate simufilam did meet its co-primary endpoints in a phase 3 trial. Those endpoints were ...

If preliminary results were correct, simufilam could be the long-sought-after cure for dementia, the Holy Grail of ...

Cassava Sciences (NASDAQ:SAVA) executive chairman and principal executive officer Rick Barry said on Monday that the company’s first Phase 3 trial of its lead drug candidate, simufilam ...

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment ...

Cassava Sciences' Phase 3 RETHINK-ALZ trial for simufilam in Alzheimer's failed decisively, with the company discontinuing its second Phase 3 trial and reducing its workforce by 33%. The company ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to ...

See . The complaint alleges that defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included, among other things, ...

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Cassava's leading drug candidate, simufilam. Defendants' statements included ...